82954
EPN · Supratentorial EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Supratentorial EPN
- cancer_type
- EPN
- subtype
- Supratentorial EPN
- age_years
- 1
- e1_e2
- E2
- umap1_2d
- -6.02456918
- umap2_2d
- 0.731722601
- umap1_3d
- 0.22220138
- umap2_3d
- 3.43889083
- umap3_3d
- 0.05932569
- dataset
- EPN-Felix
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.200
- NOTCH_SIGNALING+0.180
- BILE_ACID_METABOLISM+0.100
- PEROXISOME+0.090
- KRAS_SIGNALING_DN+0.080
- MYOGENESIS+0.080
- P53_PATHWAY+0.060
- APICAL_JUNCTION+0.050
- PANCREAS_BETA_CELLS+0.050
- COMPLEMENT+0.020
Top 10 suppressed
- E2F_TARGETS-0.560
- G2M_CHECKPOINT-0.550
- INTERFERON_ALPHA_RESPONSE-0.420
- MITOTIC_SPINDLE-0.310
- MYC_TARGETS_V2-0.300
- MYC_TARGETS_V1-0.280
- CHOLESTEROL_HOMEOSTASIS-0.230
- FATTY_ACID_METABOLISM-0.230
- INTERFERON_GAMMA_RESPONSE-0.230
- ANGIOGENESIS-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-3068 | Med | Medulloblastoma | 0.820 |
| 2 | MNG770 | — | — | 0.801 |
| 3 | GSM5359413 | — | — | 0.796 |
| 4 | C3L-02958 | — | cohortA1 | 0.795 |
| 5 | C3L-02350 | — | cohortA1 | 0.793 |
| 6 | BS_ERWT0ZWE | Med | Medulloblastoma | 0.772 |
| 7 | BS_A14Z8BBK | Med | Medulloblastoma | 0.771 |
| 8 | SRR6013517 | — | cohortA1 | 0.769 |
| 9 | SRR3147732 | — | — | 0.766 |
| 10 | TCGA-55-8097-01A-11R-2241-07 | — | cohortA1 | 0.766 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.180 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| PEROXISOME | 0.090 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.080 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.080 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.060 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.050 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.050 | Cobimetinib | — uncovered |
| COMPLEMENT | 0.020 | Inavolisib | — uncovered |
| COAGULATION | 0.010 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.010 | Inavolisib | — uncovered |